PCM Trials Completes Its Second Strategic Acquisition of 2024

On February 23, 2024, PCM Trials acquired EmVenio Research, becoming the largest independent DCT site network and the most experienced provider of local clinical trial access globally. EmVenio is a leading provider of community-based clinical trial sites served by mobile research units; its innovative network effectively reduces barriers to participation in clinical research by underrepresented communities. With the addition of EmVenio’s capabilities, PCM Trials now offers the most patient-centric model available for hybrid and decentralized clinical trials.

Read more here: https://pcmtrials.com/news/pcm-trials-acquires-emvenio-research/